FILANA THERAPEUTICS, INC.
Data quality: 83%
FLNA
Nasdaq
Manufacturing
Chemicals
$1.72
▲
$0.02
(1.18%)
Mkt Cap: 83.09 M
Price
$1.72
Mkt Cap
83.09 M
Day Range
$1.65 — $1.73
52-Week Range
$1.15 — $4.98
Volume
149,975
Open $1.68
50D / 200D Avg
$2.02
14.86% below
50D / 200D Avg
$2.49
30.91% below
Quick Summary
Key Takeaways
Negative free cash flow of -32.83 M
Growth
Revenue Growth (5Y)
N/A
Revenue (1Y)N/A
Earnings (1Y)N/A
FCF Growth (3Y)N/A
Quality
Return on Equity
-107.32%
Below sector avg (-53.41%)
ROIC-88.79%
Net MarginN/A
Op. MarginN/A
Safety
Debt / Equity
N/A
Current Ratio2.27
Interest CoverageN/A
Valuation
PE (TTM)
-0.91
Above sector avg (-1.48)
P/B Ratio1.02
EV/EBITDAN/A
Dividend YieldN/A
Price History
Financial Trends
Peer Comparison
vs Manufacturing sector median (1364 peers)
Peer Comparison
vs Manufacturing sector median (1364 peers)| Metric | Stock | Sector Median |
|---|---|---|
| P/E | -0.9 | -1.5 |
| P/B | 1.0 | 1.6 |
| ROE % | -107.3 | -53.4 |
| Net Margin % | — | -41.5 |
| Rev Growth 5Y % | — | 1.8 |
| D/E | — | 0.3 |
All Fundamental Metrics
All Fundamental Metrics
| Growth | |||
| Revenue Growth (1Y) | N/A | Revenue Growth (3Y) | N/A |
| Earnings Growth (1Y) | N/A | Earnings Growth (3Y) | N/A |
| Revenue Growth (5Y) | N/A | Earnings Growth (5Y) | N/A |
| Profitability | |||
| Revenue (TTM) | N/A | Net Income (TTM) | -90.97 M |
| ROE | -107.32% | ROA | -68.63% |
| Gross Margin | N/A | Operating Margin | N/A |
| Net Margin | N/A | Free Cash Flow (TTM) | -32.83 M |
| ROIC | -88.79% | FCF Growth (3Y) | N/A |
| Safety | |||
| Debt / Equity | N/A | Current Ratio | 2.27 |
| Interest Coverage | N/A | Asset Turnover | N/A |
| Working Capital | 60.86 M | Tangible Book Value | 81.57 M |
| Dividends | |||
| Dividend Yield | N/A | Payout Ratio | N/A |
| Dividend Growth (3Y) | N/A | Dividend Growth (5Y) | N/A |
| Consecutive Div Years | N/A | ||
| Valuation | |||
| P/E Ratio | -0.91 | Forward P/E | N/A |
| P/B Ratio | 1.02 | P/S Ratio | N/A |
| PEG Ratio | N/A | Forward PEG | N/A |
| EV/EBITDA | N/A | Fwd EV/EBITDA | N/A |
| Forward P/S | N/A | Fwd Earnings Yield | N/A |
| FCF Yield | -39.52% | ||
| Market Cap | 83.09 M | Enterprise Value | -22.99 M |
| Per Share | |||
| EPS (Diluted TTM) | -1.88 | Revenue / Share | N/A |
| FCF / Share | -0.68 | OCF / Share | -0.67 |
| EPS CAGR (1Y) | N/A | EPS CAGR (5Y) | N/A |
| EPS CAGR (10Y) | N/A | ||
| Efficiency | |||
| CapEx / Revenue | N/A | FCF Conversion | 36.09% |
| SBC-Adj. FCF | -52.65 M | Growth Momentum | N/A |
Income Statement
Annual, most recent first
Income Statement
Annual, most recent first| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | — | — | — | — | — |
| Net Income | -90.97 M | -24.34 M | -97.22 M | -76.25 M | -32.39 M |
| EPS (Diluted) | -1.88 | -1.46 | — | — | — |
| Gross Profit | — | — | — | — | — |
| Operating Income | -95.39 M | -141.45 M | -105.96 M | -80.02 M | -32.87 M |
| EBITDA | — | — | — | — | — |
| R&D Expenses | 26.59 M | 69.64 M | 89.42 M | — | — |
| SG&A Expenses | — | — | — | — | — |
| D&A | — | — | — | — | — |
| Interest Expense | — | — | — | — | — |
| Income Tax | 0.0 | 0.0 | — | — | — |
Balance Sheet
Annual, most recent first
Balance Sheet
Annual, most recent first| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Total Assets | 118.36 M | 157.53 M | 151.66 M | 234.83 M | 266.78 M |
| Total Liabilities | 43.95 M | 11.83 M | 14.20 M | 7.30 M | 12.87 M |
| Shareholders' Equity | 74.40 M | 145.70 M | 137.47 M | 227.54 M | 253.92 M |
| Total Debt | — | — | — | — | — |
| Cash & Equivalents | 95.50 M | 128.57 M | 121.14 M | 201.02 M | 233.44 M |
| Current Assets | 97.71 M | 136.53 M | 129.63 M | 211.23 M | 244.48 M |
| Current Liabilities | 43.83 M | 11.75 M | 14.20 M | 7.06 M | 12.53 M |
{"event":"ticker_viewed","properties":{"ticker":"FLNA","listing_kind":"stock","pathname":"/stocks/flna","exchange":"Nasdaq","country":"US"}}